Airway Therapeutics Joins C-Path’s International Neonatal Consortium
TUCSON, Ariz., February 15, 2023 — Critical Path Institute (C-Path) today announced that Airway Therapeutics, Inc. (“Airway”) has become a member of its International Neonatal Consortium (INC). Airway is a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases. Airway is …
First patient dosed in startup’s key Covid-19 clinical trial
Airway Therapeutics, a Sharonville-based biopharmaceutical startup, has logged another key milestone in its path toward commercialization. The company, which is developing new interventions for acute and chronic lung diseases, dosed its first patient this month in a new clinical trial aimed at patients severely impacted by Covid-19. The accomplishment is a huge step for the …
Airways Therapeutics Featured on Bio International
New Protein Replacement Therapy Makes Breathing Easier for Babies Hospitals are getting better at helping pre-term babies survive, but that help is having an unintended consequence. Each year over 160,000 pre-term babies in the US and Europe alone are at risk for developing bronchopulmonary dysplasia – or BPD. Of these pre-term babies, 49 percent will …
Airway Therapeutics Featured on TechOhio
Airway Therapeutics Helping Preemies’ Lungs Develop Written by Robert Leitch. When a baby is born prematurely, they often need mechanical ventilation and oxygenation — two medical tools that help keep preemies alive. However, these tools can also lead to inflammation and infection in the lung, which can result in bronchopulmonary dysplasia (BPD). BPD is a lung …
Airway Therapeutics in the Media
The following link provides a summary of Airway Therapeutics coverage in the news media.
